
|Videos|August 13, 2011
Dr. O'Shaughnessy on Continued Access to Avastin
Author(s)Joyce A. O'Shaughnessy, MD
Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Continued Access to Avastin
Advertisement
Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, describes that all she truly needs is access to Avastin (bevacizumab) as a treatment option for breast cancer. She believes that with its many other approvals, both in the US and in the Europe, it will continue to be accessible with a large amount of information available on its use. Having tools, such as Avastin, readily available that are non-cross resistant with chemotherapy is necessary for patients with very few options left.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
3
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
4
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
5






































































